The FDA's Teeth Get Sharper
LCGC North America
Many readers who also subscribe to LCGC's sister publication, Spectroscopy, may have read industry expert Bob McDowall's November 2009 column on the new posture of the U.S. FDA ("The Tiger Has Sharp New Teeth," Spectroscopy 24[11], 23–29 [2009]). As he saw it, "The new FDA Commissioner wants a strong FDA and is backing her words with action."
Many readers who also subscribe to LCGC's sister publication, Spectroscopy, may have read industry expert Bob McDowall's November 2009 column on the new posture of the U.S. FDA ("The Tiger Has Sharp New Teeth," Spectroscopy24[11], 23–29 [2009]). As he saw it, "The new FDA Commissioner wants a strong FDA and is backing her words with action." In light of the news coming out of Washington at the time of this writing, he may have been more correct than he imagined. Here we are just a few months later, and the internet, cable news networks, and radio talk shows are all abuzz with the latest initiative put in place by the FDA and its commissioner, Dr. Margaret Hamburg, to limit the amount of sodium Americans consume.
David Walsh
According to the Washington Post (4/20/10), "The effort would eventually lead to the first legal limits on the amount of salt allowed in processed foods," and would also lead to an unprecedented show of power on the part of not only the FDA, but the federal government in general. And while the left may cheer such a move as protecting public health and libertarians and the right may express shock at such a chilling invasion of personal freedoms, one is left to wonder what the implications of such a posture on the part of the FDA may be for the separations community in particular and laboratories in general.
At the very least, it seems to indicate that regulations such as the postinspection response program described by McDowall (initiated on September 15, 2009) will be the norm rather than the exception. And new requirements such as complete responses to 483 observations within 15 working days could be a harbinger of further regulations to come for laboratories in the U.S., rather than a one-time move.
It will be interesting to see how this initiative plays out in the realm of public opinion, where the FDA will either be emboldened to pass further regulations and restrictions (sharpening the tiger's teeth further) or chastened by public outcry. One thing is certain, we will all be hearing more on this in the weeks and months to come.
David Walsh
Editor-in-Chief
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
